Jazz Pharmaceuticals plc
JAZZHealthcareNASDAQBiotechnology · Last scanned Oct 26, 2026
Scan Results
Daily timeframeJazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. Valued at $13.89B, JAZZ is a large-cap name in its sector. The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia (IH); Epidiolex for seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC); Rylaze for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Zepzelca for the treatment of metastatic small cell lung cancer with disease progression on or after platinum-based chemotherapy; Ziihera to treat HER2-positive biliary tract cancers; Modeyso for the treatment of diffuse midline glioma harboring an H3 K27M mutation; and Defitelio to treat severe veno-occlusive disease.
Market Cap
$13.89B
Beta
0.37
P/E (TTM)
14.67
P/E (Fwd)
8.25
EPS (TTM)
$14.59
EPS (Fwd)
$25.94
ROE
22.1%
ROA
6.9%
Cash
$2.20B
Total Debt
$4.41B
Free CF
$1.43B
52W Change
53.6%
Annual Financials
Cash vs Debt
Where JAZZ stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, JAZZ finished 8.84% below its 150-day moving average ($228.64) and 2.90% below its 200-day moving average ($214.66). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is JAZZ overbought or oversold?
At the October 20, 2026 close, JAZZ's RSI(14) was 21.9, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The company holds $2.20B in cash, though total debt stands at $4.41B. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. Free cash flow comes in at $1.43B, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. Return on equity stands at 22.1%, which is strong for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. An ROA of 6.9% suggests reasonable efficiency in deploying the company's asset base. Revenue has been uneven over recent years, ranging from $3.66B to $4.27B.
With a beta below 0.7, Jazz Pharmaceuticals plc typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Jazz Pharmaceuticals plc's trajectory.